The patent will be formally approved on October 27, 2020
Follicum has announced its patent, which in June received a so-called Notice of Allowance from the US Patent and Trademark Office (USPTO), has now also been formally approved by the authority. The patent is called "Peptides for Treatment of Diabetes" and will be valid until 2038.
The patent (US 10815283) covers peptides from the company's two peptide classes and their use in the treatment of diabetes and its complications.
CEO Jan Alenfall said: "The US is by far the largest market for Follicum in diabetes and its complications. This formal patent approval is therefore of great importance to us and an important step in our global patent strategy. We are continuously working to expand our patent portfolio in our key markets.”